Metronomics in Pediatric Oncology: Lessons Learned and the Way Forward

Raja Pramanik; Sameer Bakhshi

doi:10.4103/ijmpo.ijmpo_22_20

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(03): 317-318
DOI: 10.4103/ijmpo.ijmpo_22_20

Editorial Commentary

Metronomics in Pediatric Oncology: Lessons Learned and the Way Forward

Raja Pramanik

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

,

Sameer Bakhshi

Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India

› Author Affiliations

Abstract

Full Text

References

References
1 Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: A neglected but crucial aspect. Nat Rev Clin Oncol 2016; 13: 659-73
2 André N, Carré M, Pasquier E. Metronomics: Towards personalized chemotherapy?. Nat Rev Clin Oncol 2014; 11: 413-31
3 Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother 2014; 5: 186-92
4 Bahl A, Bakhshi S. Metronomic chemotherapy in progressive pediatric malignancies: Old drugs in new package. Indian J Pediatr 2012; 79: 1617-22
5 Pramanik R, Bakhshi S. Metronomic therapy in pediatric oncology: A snapshot. Pediatr Blood Cancer 2019; 66: e27811
6 Kerbel RS. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. Cancer Res Treat 2007; 39: 150-9
7 Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 2010; 7: 455-65
8 Pramanik R, Agarwala S, Gupta YK, Thulkar S, Vishnubhatla S, Batra A. et al. Metronomic chemotherapy vs. best supportive care in progressive pediatric solid malignant tumors: A randomized clinical trial. JAMA Oncol 2017; 3: 1222-7
9 Bisogno G, De Salvo GL, Bergeron C, Jenney M, Merks JH, Minard-Colin V. et al. Maintenance low-dose chemotherapy in patients with high-risk (HR) rhabdomyosarcoma (RMS): A report from the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG). J Clin Oncol 2018; 36 18 Suppl: LBA2
10 Koscielniak E, Klingebiel T. A new standard of care for patients with high-risk rhabdomyosarcoma?. Lancet Oncol 2020; 21: e1
11 Pramanik R, Tyagi A, Agarwala S, Vishnubhatla S, Dhawan D, Bakhshi S. Evaluation of Vascular Endothelial Growth Factor (VEGF) and Thrombospondin-1 as Biomarkers of Metronomic Chemotherapy in Progressive Pediatric Solid Malignancies [published online ahead of print, 2020 Mar 12]. Indian Pediatr. 2020;S097475591600146
12 Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: A neglected but crucial aspect. Nat Rev Clin Oncol 2016; 13: 659-73
13 Barbolosi D, Ciccolini J, Meille C, Elharrar X, Faivre C, Lacarelle B. et al. Metronomics chemotherapy: Time for computational decision support. Cancer Chemother Pharmacol 2014; 74: 647-52